MA49512A - Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation - Google Patents
Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisationInfo
- Publication number
- MA49512A MA49512A MA049512A MA49512A MA49512A MA 49512 A MA49512 A MA 49512A MA 049512 A MA049512 A MA 049512A MA 49512 A MA49512 A MA 49512A MA 49512 A MA49512 A MA 49512A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- binding proteins
- human anti
- papillomavirus antigen
- papillomavirus
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762525937P | 2017-06-28 | 2017-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49512A true MA49512A (fr) | 2020-05-06 |
Family
ID=63080480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049512A MA49512A (fr) | 2017-06-28 | 2018-06-27 | Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation |
Country Status (16)
Country | Link |
---|---|
US (3) | US10806780B2 (fr) |
EP (1) | EP3645562A1 (fr) |
JP (2) | JP7401312B2 (fr) |
CN (1) | CN110914295B (fr) |
AU (1) | AU2018290856A1 (fr) |
BR (1) | BR112019027211A2 (fr) |
CA (1) | CA3066779A1 (fr) |
CL (2) | CL2019003802A1 (fr) |
CO (1) | CO2020000733A2 (fr) |
EA (1) | EA202090149A1 (fr) |
IL (2) | IL299348A (fr) |
MA (1) | MA49512A (fr) |
MX (2) | MX2019015477A (fr) |
PH (1) | PH12019502763A1 (fr) |
SG (1) | SG11201912240QA (fr) |
WO (1) | WO2019005897A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202090149A1 (ru) | 2017-06-28 | 2020-05-31 | Ридженерон Фармасьютикалз, Инк. | Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения |
SG11202002728VA (en) | 2017-10-03 | 2020-04-29 | Juno Therapeutics Inc | Hpv-specific binding molecules |
TWI840351B (zh) | 2018-04-05 | 2024-05-01 | 美商奇諾治療有限公司 | T細胞受體及表現其之工程化細胞 |
MX2022007754A (es) | 2019-12-20 | 2022-07-19 | Regeneron Pharma | Nuevos agonistas de il2 y metodos de uso de estos. |
HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
CN111410689B (zh) * | 2020-03-16 | 2021-11-02 | 重庆理工大学 | 抗hpv16e7蛋白单抗69e2、杂交瘤细胞株及其制备方法和应用 |
CN111333720B (zh) * | 2020-03-16 | 2021-11-02 | 重庆理工大学 | 抗hpv16e7蛋白单抗79a11、杂交瘤细胞株及其制备方法和应用 |
CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
WO2023022965A2 (fr) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Nouveaux agonistes du récepteur d'il27 et procédés d'utilisation associés |
WO2023133193A1 (fr) * | 2022-01-05 | 2023-07-13 | Memorial Sloan-Kettering Cancer Center | Anticorps anti-hpv et leurs utilisations |
WO2024151978A1 (fr) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Agonistes du récepteur d'il12 et leurs procédés d'utilisation |
WO2024182540A2 (fr) | 2023-02-28 | 2024-09-06 | Regeneron Pharmaceuticals, Inc. | Activateurs de lymphocytes t et leurs procédés d'utilisation |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
WO1989002468A1 (fr) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Fibroblastes transduits et leurs applications |
DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Hughes Howard Med Inst | Genetische modifizierung von endothelialen zellen. |
EP0732397A3 (fr) | 1988-02-05 | 1996-10-23 | Whitehead Institute For Biomedical Research | Hepatocytes modifiés et leur emplois |
US5180806A (en) * | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
EP0451550A3 (en) * | 1990-03-20 | 1991-11-06 | Behringwerke Aktiengesellschaft | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
CN1067382A (zh) * | 1990-09-26 | 1992-12-30 | 布里斯托尔-迈尔斯斯奎尔公司 | 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用 |
EP0568537B1 (fr) | 1990-10-31 | 1998-02-04 | Somatix Therapy Corporation | Modification genetique de cellules endotheliales |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP1425039A4 (fr) * | 2001-03-23 | 2005-02-02 | Us Gov Health & Human Serv | Peptides immunoreactifs du papillomavirus humain |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
CO5770113A1 (es) * | 2006-04-28 | 2007-06-29 | Fundacion Inst De Inmunologia De Colombia | Peptidos para detectar o inducir la produccion de anticuerpos anti el virus de pailoma humano, anti la proteina l1 o anti peptidos de esta proteina |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
JP5707326B2 (ja) * | 2008-09-02 | 2015-04-30 | アンティジェン・エクスプレス・インコーポレーテッドAntigen Express,Inc. | ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法 |
CN102471378B (zh) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
CN102443060B (zh) * | 2010-10-13 | 2014-04-30 | 上海泽润生物科技有限公司 | 一种抗hpv的抗体、其制备方法和应用 |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
AU2012214132B2 (en) | 2011-02-11 | 2016-07-28 | Memorial Sloan-Kettering Cancer Center | HLA-restricted, peptide-specific antigen binding proteins |
CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
EP2567972A1 (fr) * | 2011-09-12 | 2013-03-13 | Adriacell S.p.A. | Anticorps contre la protéine E7 du virus du papillome humain |
CN102719402B (zh) * | 2012-07-05 | 2014-05-14 | 时宏珍 | Hla-a0201限制性抗hpv抗原特异性ctl的制备方法 |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
EP3572423B1 (fr) * | 2013-07-15 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Récepteurs de lymphocytes t anti-papillomavirus humain 16 e6 |
EP2883550A1 (fr) | 2013-12-12 | 2015-06-17 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Nouveaux épitopes de lymphocytes T auxiliaires dérivés d'un HPV16 multivalents pour l'immunothérapie |
US10174098B2 (en) * | 2014-05-29 | 2019-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 E7 T cell receptors |
EP3220926A4 (fr) | 2014-11-17 | 2018-08-08 | Adicet Bio Inc. | Lymphocytes t gamma delta produits par génie génétique |
WO2016182957A1 (fr) | 2015-05-08 | 2016-11-17 | Eureka Therapeutics, Inc. | Constructions ciblant les complexes mhc/peptide hpv16-e7 et leurs utilisations |
CN105131113B (zh) * | 2015-08-26 | 2019-09-06 | 艾托金生物医药(苏州)有限公司 | 用于宫颈癌检测和分级的单隆抗体及其应用 |
MX2019003768A (es) | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
EA202090149A1 (ru) | 2017-06-28 | 2020-05-31 | Ридженерон Фармасьютикалз, Инк. | Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения |
-
2018
- 2018-06-27 EA EA202090149A patent/EA202090149A1/ru unknown
- 2018-06-27 EP EP18749628.6A patent/EP3645562A1/fr active Pending
- 2018-06-27 SG SG11201912240QA patent/SG11201912240QA/en unknown
- 2018-06-27 BR BR112019027211-9A patent/BR112019027211A2/pt unknown
- 2018-06-27 MX MX2019015477A patent/MX2019015477A/es unknown
- 2018-06-27 US US16/019,703 patent/US10806780B2/en active Active
- 2018-06-27 IL IL299348A patent/IL299348A/en unknown
- 2018-06-27 MA MA049512A patent/MA49512A/fr unknown
- 2018-06-27 WO PCT/US2018/039654 patent/WO2019005897A1/fr unknown
- 2018-06-27 JP JP2019571685A patent/JP7401312B2/ja active Active
- 2018-06-27 CN CN201880044309.7A patent/CN110914295B/zh active Active
- 2018-06-27 CA CA3066779A patent/CA3066779A1/fr active Pending
- 2018-06-27 AU AU2018290856A patent/AU2018290856A1/en active Pending
-
2019
- 2019-12-05 PH PH12019502763A patent/PH12019502763A1/en unknown
- 2019-12-06 IL IL271231A patent/IL271231B2/en unknown
- 2019-12-18 MX MX2024002706A patent/MX2024002706A/es unknown
- 2019-12-20 CL CL2019003802A patent/CL2019003802A1/es unknown
-
2020
- 2020-01-23 CO CONC2020/0000733A patent/CO2020000733A2/es unknown
- 2020-08-13 US US16/992,188 patent/US11559576B2/en active Active
-
2021
- 2021-12-16 CL CL2021003368A patent/CL2021003368A1/es unknown
-
2022
- 2022-12-15 US US18/081,782 patent/US20230270837A1/en active Pending
-
2023
- 2023-12-07 JP JP2023206822A patent/JP2024026308A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024026308A (ja) | 2024-02-28 |
US20220001000A1 (en) | 2022-01-06 |
EP3645562A1 (fr) | 2020-05-06 |
CA3066779A1 (fr) | 2019-01-03 |
US10806780B2 (en) | 2020-10-20 |
IL271231A (en) | 2020-01-30 |
US20190000956A1 (en) | 2019-01-03 |
AU2018290856A1 (en) | 2020-01-02 |
CL2021003368A1 (es) | 2022-08-19 |
CL2019003802A1 (es) | 2020-06-12 |
IL271231B1 (en) | 2023-01-01 |
US20230270837A1 (en) | 2023-08-31 |
KR20200022467A (ko) | 2020-03-03 |
SG11201912240QA (en) | 2020-01-30 |
WO2019005897A1 (fr) | 2019-01-03 |
EA202090149A1 (ru) | 2020-05-31 |
IL271231B2 (en) | 2023-05-01 |
JP7401312B2 (ja) | 2023-12-19 |
JP2020529835A (ja) | 2020-10-15 |
PH12019502763A1 (en) | 2020-06-08 |
BR112019027211A2 (pt) | 2020-06-30 |
US11559576B2 (en) | 2023-01-24 |
CN110914295B (zh) | 2024-08-09 |
MX2019015477A (es) | 2020-07-28 |
IL299348A (en) | 2023-02-01 |
CO2020000733A2 (es) | 2020-01-31 |
MX2024002706A (es) | 2024-03-20 |
CN110914295A (zh) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49512A (fr) | Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation | |
MA47113A (fr) | Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA43816A (fr) | Protéines de liaison inductibles et méthodes d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42428A (fr) | Anticorps humanisés et à maturation d'affinité dirigés contre fcrh5 et méthodes d'utilisation | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA48852A (fr) | Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation | |
MA56165A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation |